Sagimet Biosciences Inc. Series A Common Stock

$5.56
(as of Jun 6, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Sagimet Biosciences Inc. Series A Common Stock

Stock Price
$5.56
Ticker Symbol
SGMT
Exchange
NASDAQ

Industry Information for Sagimet Biosciences Inc. Series A Common Stock

Sector
Healthcare
Industry
Biotechnology

Company Description for Sagimet Biosciences Inc. Series A Common Stock

Website
https://www.sagimet.com
Country
USA
Full Time Employees
14

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Fundamentals for Sagimet Biosciences Inc. Series A Common Stock

Market Capitalization
$106,566,440
EBITDA
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.45
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
30,674,900
Percent Owned by Insiders
14.65%
Percent Owned by Institutions
57.99%
52-Week High
52-Week Low

Technical Indicators for Sagimet Biosciences Inc. Series A Common Stock

50-Day Moving Average
200-Day Moving Average
RSI
76.92
ATR
0.4

Analyst Ratings for Sagimet Biosciences Inc. Series A Common Stock

Strong Buy
5
Buy
3
Hold
1
Sell
0
Strong Sell
0

News About Sagimet Biosciences Inc. Series A Common Stock

Jun 4, 2025, 4:03 PM EST
Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index up 0.6% and See more.
Jun 4, 2025, 6:54 AM EST
[acne skin layer, Skin treatments , cosmetology and skincare problems. 3d rendering.] See more.
Jun 4, 2025, 6:19 AM EST
(RTTNews) - Sagimet Biosciences (SGMT) reported that denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial for the treatment of moderate to severe acne vulgaris conducted by Sagimets license partner Ascletis Bioscience in China. See more.
Jun 4, 2025, 5:00 AM EST
Denifanstat met all primary and secondary endpoints versus placebo See more.